Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Who can take part

• Age ≥ 6 years old and ≤ 17 years old,both sexes
• Part A:Confirmed diagnosis of ITP ≥6months; Part B: Confirmed diagnosis of ITP ≥12months;Platelets <30×10\^9/L twice in a row,and platelets <30×10\^9/L before taking the medicine
• Subjects who are refractory or have relapsed after at least one prior ITP therapy
• Birth control during and 28 days after the trial
• Written informed consent must be obtained from the patient's guardian and accompanying informed assent from the patient (for children over 8 years old)

Who cannot take part

• Patients with any prior history of arterial or venous thrombosis, or diagnosis as thrombophilia
• Participated in clinical trials of other drugs (received experimental drugs) within 3 months prior to medication
• Suffering from serious, progressive, uncontrolled kidney, liver, gastrointestinal, endocrine, lung, heart, nervous system, brain, or mental illness
• Active HIV or HCV-Ab positive,HBsAg positive
• The inestigators determined that other conditions were inappropriate for participation in this clinical trial
• ALT, AST, or ALP> 1.5 x upper limit of normal (ULN), DBLI, or Scr > 1.2 x upper limit of normal (ULN)
• PT result exceeds normal by more than ±3s, APTT result exceeds normal by more than ±10s
• No evidence of other causes of thrombocytopenia
• Diagnosis as Evans or Wiskott-Aldrich comprehensive